Journal
The Medicaid GLP-1 Change Ledger: Every 2025–2026 State Move, Dated and Sourced
Released: Last reviewed:
The short answer
State Medicaid coverage of GLP-1s for weight loss changed more in the past year than in the prior decade, and mostly downward: KFF counted thirteen covering states in January 2026, down from sixteen the previous fall, and independent trackers counted roughly eleven by mid-2026. The dated moves on this ledger: North Carolina reinstated coverage December 12, 2025 (primary source: the state's own bulletin); California's Medi-Cal ended weight-loss coverage January 1, 2026 (primary source: DHCS bulletins); tracker-documented 2026 exits include Utah's pilot ending June 30 and Massachusetts ending July 1, plus Rhode Island ending weight-loss-only coverage October 1, 2026 per a Medicaid plan's provider notice, with Pennsylvania and New Hampshire reported ended and Colorado and West Virginia having rolled back earlier. Diabetes-indication coverage continued everywhere throughout, as did the federal non-weight indication doors. Each entry below carries its date, its source, and — in this site's house style — its evidentiary status.
How this ledger works
Three evidentiary tiers, printed on every entry, descending: primary — the state Medicaid agency's own bulletin, notice, or preferred-drug-list change; tracker-reported — a named national tracker or policy review reporting the change (useful, dated, but secondhand); press-reported — news coverage only. A member's actual answer always lives one tier above anything here: the state pharmacy desk or current PDL on the day of the question. The ledger's job is different — to preserve the dates, because the single most common Medicaid-GLP-1 error in circulation is a true statement from the wrong month, and North Carolina alone generated three different true answers inside eighteen months.
The 2025–2026 entries
Colorado; West Virginia — rolled back or paused, 2025. Status: tracker-reported (the December 2025 state-by-state review circulated by Delaware's benefits office names both, alongside North Carolina's pause). West Virginia's earlier pilot-and-cancellation is the class's original cost cautionary tale. North Carolina — reinstated effective December 12, 2025. Status: primary; the December 19, 2025 NC Medicaid bulletin restores the September 30, 2025 criteria across Medicaid Direct and Managed Care — the full record is our North Carolina page. California — ended January 1, 2026 for adults twenty-one and older; Wegovy, Zepbound, and Saxenda off the Contract Drug List for weight indications. Status: primary; DHCS Medi-Cal Rx bulletins and plan implementation notices, documented on our California page. New Hampshire; Pennsylvania — ended. Status: tracker-reported (both appear on 2026 coverage trackers' ended lists; Pennsylvania's exit is notable because it had been among the longest-standing covering states). Utah — pilot ended June 30, 2026 with no renewal enacted. Status: tracker-reported (The RX Index, July 2026). Massachusetts — ended July 1, 2026. Status: tracker-reported (multiple trackers; MassHealth had signaled the shift in advance). Rhode Island — weight-loss-only coverage ended October 1, 2026. Foundayo, Saxenda, Wegovy and Zepbound are no longer covered when prescribed solely for weight loss; coverage continues for type 2 diabetes and other FDA-approved indications. Status: plan-notice sourced (Point32Health/Tufts Health RITogether provider notice); full record on our Rhode Island page. The counts: KFF, January 2026 — thirteen states, down from sixteen the prior fall (status: tracker-reported, from the field's most-cited source); The RX Index, July 10, 2026 — eleven states verified covering (Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Virginia, Wisconsin), nearly all with prior authorization and several with BMI thresholds, step therapy, or age rules. Rhode Island has since left that list for weight-loss-only use (October 1, 2026).
The federal overlay, and what to watch
Two federal timelines run alongside the state churn, per KFF's January 2026 analysis: the CMS Innovation Center's BALANCE model, announced December 2025, a five-year model intended to expand obesity-drug access in Medicaid, while on the Medicare side CMS's model page (modified September 29, 2026) carries an FAQ about "the BALANCE Model not launching in Medicare in 2027"; and the separate Medicare GLP-1 Bridge, which began July 1, 2026 and has been extended through December 31, 2027 ($50 copay for eligible Part D enrollees; per Medicare.gov it covers Foundayo, Wegovy and the Zepbound KwikPen, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for it) — the mechanics of which live in our Medicare guide. Neither changes the underlying legal structure this whole ledger runs on: federal rebate rules let states exclude only the weight-loss use, which is why the non-weight indication doors — cardiovascular, sleep apnea, kidney, MASH, and diabetes itself — kept working in every state on this page through every entry above. Watch-list for the next update: whether BALANCE participation announcements move any state back into the covering column — enrollment is rolling through January 1, 2027 per CMS, so an announcement can land any month, tracked on the BALANCE explainer — the fate of the tracker-reported FY2027 restrictions, and each covering state's budget session, with Minnesota's delayed prohibition bill and the Wisconsin restriction discussion as named items. One dated addition to the record: Virginia tightened its service-authorization criteria mid-2026 — a DMAS bulletin set the standard at BMI forty or higher, or thirty-five with two or more chronic conditions, with the updated form reported effective July 1, 2026 (primary source, detailed on the Virginia record). Detailed state records now exist for every covering state: Michigan, Minnesota, Wisconsin, Virginia, Delaware, Kansas, Mississippi, Missouri, and Tennessee, alongside California, Rhode Island and North Carolina. Entries are added as documented; a state bulletin a reader sends to the corrections desk upgrades a tracker-reported entry to primary, which is the entire point of running this as a ledger.
Questions people ask
How many states cover GLP-1s for weight loss under Medicaid in 2026?
Thirteen at KFF's January 2026 count (down from sixteen the previous fall); roughly eleven by mid-2026 per The RX Index's July verification — Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Virginia, and Wisconsin — nearly always with prior authorization and often with BMI, step-therapy, or age limits. Rhode Island has since ended coverage for weight loss alone, effective October 1, 2026.
Which states dropped Medicaid GLP-1 weight-loss coverage recently?
The dated 2025–2026 exits on record: California (January 1, 2026, primary-sourced), Utah's pilot end (June 30, 2026) and Massachusetts (July 1, 2026) per trackers, with Pennsylvania and New Hampshire tracker-reported ended and Colorado and West Virginia having rolled back earlier. Rhode Island followed on October 1, 2026, ending coverage of GLP-1s prescribed solely for weight loss (per a Point32Health/Tufts Health RITogether provider notice). North Carolina moved the other way, reinstating December 12, 2025.
Does Medicaid still cover GLP-1s for diabetes everywhere?
Yes — every state covers the class for type 2 diabetes with prior authorization, and the federal medically-accepted-indication rules keep the non-weight doors (cardiovascular, sleep apnea, kidney disease, MASH) generally available nationwide. Only the weight-loss use is excludable state by state.
How do I find out my state's current Medicaid GLP-1 policy?
One tier above any list, including this one: your state Medicaid pharmacy desk or its current preferred drug list, checked on the day you need the answer. This ledger preserves the dated record precisely because the most common error in circulation is last year's true answer presented as this year's.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.